Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Monte Rosa Therapeutics, Inc. Market Cap
From what 8 stock analysts predict, the share price for Monte Rosa Therapeutics, Inc. (GLUE) might increase by 74.03% in the next year. This is based on a 12-month average estimation for GLUE. Price targets go from $14 to $20. The majority of stock analysts believe GLUE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assignedGLUE 8 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Monte Rosa Therapeutics, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GLUE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of GLUE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Robert Driscoll Wedbush | Outperform | $11 | Reiterates | Sep 12, 2024 |
| Derek Archila Wells Fargo | Overweight | $17 | Maintains | Aug 12, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $16 | Reiterates | Jun 28, 2024 |
| Robert Driscoll Wedbush | Outperform | $11 | Reiterates | May 22, 2024 |
| Robert Driscoll Wedbush | Outperform | $11 | Initiates | Feb 15, 2024 |
| Eric Joseph JP Morgan | Overweight | $11 | Maintains | Oct 19, 2023 |
| Richard Law Credit Suisse | Neutral | $11 | Reiterates | Aug 11, 2023 |
| Richard Law Credit Suisse | Neutral | $11 | Reiterates | May 12, 2023 |
| Richard Law Credit Suisse | Neutral | $11 | Maintains | Mar 17, 2023 |
| Derek Archila Wells Fargo | Overweight | $19 | Upgrade | Jan 3, 2023 |
| Eliana Merle UBS | Buy | $22 | Initiates | Oct 13, 2022 |
Credit Suisse | Neutral | Initiates | Aug 22, 2022 | |
| Kelly Shi Jefferies | Buy | $20 | Initiates | Aug 15, 2022 |
| Edward Tenthoff Piper Sandler | Overweight | $21 | Maintains | May 12, 2022 |
Credit Suisse | Neutral | Initiates | Apr 28, 2022 | |
Wells Fargo | Equal-Weight | Initiates | Feb 10, 2022 | |
SVB Leerink | Market Perform | Initiates | Oct 14, 2021 | |
Guggenheim | Buy | Initiates | Jul 19, 2021 | |
Piper Sandler | Overweight | Initiates | Jul 19, 2021 | |
JP Morgan | Overweight | Initiates | Jul 19, 2021 |
When did it IPO
2021
Staff Count
133
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Markus Warmuth M.D.
Market Cap
$559.7M
In 2023, GLUE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GLUE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Monte Rosa Therapeutics reported favorable safety results for MRT-2359 in a Phase 1/2 study, with a recommended Phase 2 dose of 0.5 mg daily. Further results expected Q1 2025.
Why It Matters - Positive Phase 1/2 results for MRT-2359 indicate potential for effective treatment in solid tumors, enhancing Monte Rosa's growth prospects and likely impacting stock performance.
Mon, 02 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for Monte Rosa Therapeutics (GLUE) suggest a potential 64.1% upside, supported by a consensus on raised earnings estimates.
Why It Matters - Analysts predict a 64.1% upside for Monte Rosa Therapeutics, suggesting potential growth. Consensus on rising earnings estimates further supports positive sentiment for the stock.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Monte Rosa Therapeutics (Nasdaq: GLUE) CEO Markus Warmuth will speak at the Piper Sandler Healthcare Conference on December 3, 2024, at 3:30 p.m.
Why It Matters - CEO participation in a major healthcare conference can signal company growth potential and foster investor interest, impacting stock performance and market perception of Monte Rosa Therapeutics.
Fri, 15 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for Monte Rosa Therapeutics (GLUE) suggest a 100.5% upside, supported by increased earnings estimates, despite mixed effectiveness of price targets.
Why It Matters - Analysts' price targets suggesting a 100.5% upside, coupled with increased earnings estimates, signals potential growth for Monte Rosa Therapeutics (GLUE), attracting investor interest.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Monte Rosa Therapeutics (GLUE) reported a quarterly loss of $0.29 per share, better than the expected loss of $0.45 and an improvement from a loss of $0.70 per share a year prior.
Why It Matters - Monte Rosa's smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Wed, 06 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Monte Rosa Therapeutics (GLUE) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters - The inquiry into Monte Rosa Therapeutics as a momentum stock signals potential volatility and growth, prompting investors to assess its performance and market sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
